Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | F2R | P25116 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPRA | P18433 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567258 | 0.91 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL27501194 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL6272750 | 0.89 | HPGD (0.74) | SMN1; SMN2NPC1RAB9AF2RHTT | |
| SCHEMBL21998902 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL21999362 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL7821193 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL12430335 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL21998688 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL7822881 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL7824612 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614074-A | Amino acid derivatives for the treatment of inflammatory diseases | 罗斯坎普研究所 | 2021-11-05 | — | — | CN | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-0069664-A1 | Aminobenzamides, their salts, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 3472/4885NPC1 601/4885RAB9A 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.